uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-1723
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis ; volume:9 ; number:1 ; day:5 ; month:12 ; year:2018 ; pages:1-16 ; date:12.2018
Nature Communications ; 9, Heft 1 (5.12.2018), 1-16, 12.2018
- Urheber
-
Durré, Tania
Morfoisse, Florent
Erpicum, Charlotte
Ebroin, Marie
Blacher, Silvia
García-Caballero, Melissa
Deroanne, Christophe
Louis, Thomas
Balsat, Cédric
Van de Velde, Maureen
Kaijalainen, Seppo
Kridelka, Frédéric
Engelholm, Lars
Struman, Ingrid
Alitalo, Kari
Behrendt, Niels
Paupert, Jenny
Noel, Agnès
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-018-07514-1
- URN
-
urn:nbn:de:101:1-2019011916190270181043
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Durré, Tania
- Morfoisse, Florent
- Erpicum, Charlotte
- Ebroin, Marie
- Blacher, Silvia
- García-Caballero, Melissa
- Deroanne, Christophe
- Louis, Thomas
- Balsat, Cédric
- Van de Velde, Maureen
- Kaijalainen, Seppo
- Kridelka, Frédéric
- Engelholm, Lars
- Struman, Ingrid
- Alitalo, Kari
- Behrendt, Niels
- Paupert, Jenny
- Noel, Agnès
- SpringerLink (Online service)
Ähnliche Objekte (12)
Regulation of lymphangiogenesis in the diaphragm by macrophages and VEGFR-3 signaling
Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway
Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases
Enhancement of cardiac lymphangiogenesis by transplantation of CD34+VEGFR-3+ endothelial progenitor cells and sustained release of VEGF-C
Vascular endothelial growth factor (VEGF)-C and its receptors, soluble VEGFR-2 and VEGFR-3, in polycystic ovary syndrome
Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15
Veränderung der Expression von VEGF, VEGFR-1, VEGFR-2, MMP12 und Rab23 in der Lunge von Patienten mit parenchymatösen Lungenerkrankungen
Der differentielle Einfluss der beiden VEGF-Rezeptoren VEGFR-1 und VEGFR-2 auf die Genexpression von PIGF und MCP-1
VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody
Correction: VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody
The molecular function of CD44v6 for the receptor tyrosine kinases Met and VEGFR-2
Regulation of lymphangiogenesis in the diaphragm by macrophages and VEGFR-3 signaling
Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway
Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases
Enhancement of cardiac lymphangiogenesis by transplantation of CD34+VEGFR-3+ endothelial progenitor cells and sustained release of VEGF-C
Vascular endothelial growth factor (VEGF)-C and its receptors, soluble VEGFR-2 and VEGFR-3, in polycystic ovary syndrome
Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15
Veränderung der Expression von VEGF, VEGFR-1, VEGFR-2, MMP12 und Rab23 in der Lunge von Patienten mit parenchymatösen Lungenerkrankungen
Der differentielle Einfluss der beiden VEGF-Rezeptoren VEGFR-1 und VEGFR-2 auf die Genexpression von PIGF und MCP-1
VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody
Correction: VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody
The molecular function of CD44v6 for the receptor tyrosine kinases Met and VEGFR-2
Regulation of lymphangiogenesis in the diaphragm by macrophages and VEGFR-3 signaling
Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway
Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases
Enhancement of cardiac lymphangiogenesis by transplantation of CD34+VEGFR-3+ endothelial progenitor cells and sustained release of VEGF-C
Vascular endothelial growth factor (VEGF)-C and its receptors, soluble VEGFR-2 and VEGFR-3, in polycystic ovary syndrome
Counterbalance: modulation of VEGF/VEGFR activities by TNFSF15
Veränderung der Expression von VEGF, VEGFR-1, VEGFR-2, MMP12 und Rab23 in der Lunge von Patienten mit parenchymatösen Lungenerkrankungen
Der differentielle Einfluss der beiden VEGF-Rezeptoren VEGFR-1 und VEGFR-2 auf die Genexpression von PIGF und MCP-1
VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody
Correction: VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody